[{"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-001", "question": "A 45-year-old man with a history of bipolar disorder presents with acute agitation, auditory hallucinations, and disorganized thinking after discontinuing his lithium therapy 2 weeks ago. He has a serum creatinine of 1.8 mg/dL and reports recent use of ibuprofen for headaches. Which of the following is the most appropriate initial management?", "options": ["Administer haloperidol intramuscularly", "Restart lithium at half the previous dose", "Initiate valproic acid orally", "Perform hemodialysis", "Administer lorazepam intravenously"], "answer": "D", "answer_index": 3, "explanation": "Hemodialysis is indicated due to lithium toxicity exacerbated by NSAID-induced renal impairment, leading to elevated lithium levels causing neurotoxicity. Haloperidol and lorazepam address symptoms but not the underlying toxicity, while restarting lithium or starting valproic acid risks worsening the condition without clearance.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed—the keyed answer is not defensible. The stem describes a patient who discontinued lithium 2 weeks ago presenting with acute psychotic symptoms (agitation, hallucinations, disorganized thinking). Key discriminating findings: (1) lithium stopped 2 weeks prior, (2) elevated creatinine 1.8 mg/dL with recent NSAID use, (3) acute psychiatric decompensation. The clinical problem is acute psychotic agitation in bipolar disorder after medication discontinuation. The rationale claims lithium toxicity, but this is medically implausible—lithium has a half-life of ~24 hours; after 2 weeks off therapy, lithium levels would be negligible/undetectable. The elevated creatinine likely reflects NSAID-induced acute kidney injury, not lithium toxicity. No lithium level is provided to support toxicity. Hemodialysis (D) is not indicated without documented toxic lithium levels and appropriate clinical syndrome. The correct management for acute psychotic agitation is immediate symptom control: haloperidol IM (A) or lorazepam IV (E) are both defensible, with A slightly preferred for primary psychotic symptoms. The item confuses lithium discontinuation syndrome (relapse) with lithium toxicity. Minimal fix: Either provide a lithium level showing toxicity to justify D, or remove the toxicity premise and key to A for acute agitation management.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed—the keyed answer is not defensible. The stem describes a patient who discontinued lithium 2 weeks ago presenting with acute psychotic symptoms (agitation, hallucinations, disorganized thinking). Key discriminating findings: (1) lithium stopped 2 weeks prior, (2) elevated creatinine 1.8 mg/dL with recent NSAID use, (3) acute psychiatric decompensation. The clinical problem is acute psychotic agitation in bipolar disorder after medication discontinuation. The rationale claims lithium toxicity, but this is medically implausible—lithium has a half-life of ~24 hours; after 2 weeks off therapy, lithium levels would be negligible/undetectable. The elevated creatinine likely reflects NSAID-induced acute kidney injury, not lithium toxicity. No lithium level is provided to support toxicity. Hemodialysis (D) is not indicated without documented toxic lithium levels and appropriate clinical syndrome. The correct management for acute psychotic agitation is immediate symptom control: haloperidol IM (A) or lorazepam IV (E) are both defensible, with A slightly preferred for primary psychotic symptoms. The item confuses lithium discontinuation syndrome (relapse) with lithium toxicity. Minimal fix: Either provide a lithium level showing toxicity to justify D, or remove the toxicity premise and key to A for acute agitation management.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-002", "question": "A 32-year-old woman with schizophrenia on clozapine develops fever, tachycardia, and muscle rigidity. Laboratory findings include elevated creatine kinase and leukocytosis. Which rare adverse effect is most likely responsible, and what is the next step in management?", "options": ["Agranulocytosis; discontinue clozapine and start G-CSF", "Neuroleptic malignant syndrome; administer dantrolene and bromocriptine", "Serotonin syndrome; give cyproheptadine", "Catatonia; initiate electroconvulsive therapy", "Myocarditis; perform echocardiography and stop clozapine"], "answer": "B", "answer_index": 1, "explanation": "Neuroleptic malignant syndrome is the diagnosis, requiring immediate supportive care with dantrolene for rigidity and bromocriptine for dopamine agonism. Agranulocytosis presents with infection without rigidity, serotonin syndrome lacks CK elevation typically, catatonia is behavioral, and myocarditis involves cardiac symptoms primarily.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a classic triad of fever, muscle rigidity, and elevated CK in a patient on an antipsychotic (clozapine), which is pathognomonic for neuroleptic malignant syndrome (NMS). Key discriminating findings include: (1) antipsychotic exposure, (2) fever + tachycardia (autonomic instability), (3) muscle rigidity (extrapyramidal), (4) elevated CK (rhabdomyolysis), and (5) leukocytosis. Option B correctly identifies NMS and appropriate management with dantrolene (muscle relaxant) and bromocriptine (dopamine agonist), plus supportive care and drug discontinuation. Option A: agranulocytosis presents with infection/neutropenia, not rigidity or elevated CK. Option C: serotonin syndrome typically shows hyperreflexia/clonus rather than lead-pipe rigidity, and CK elevation is less prominent. Option D: catatonia lacks the autonomic instability and marked CK elevation. Option E: clozapine myocarditis presents with chest pain, dyspnea, troponin elevation, and ECG changes—not the neuromuscular syndrome described. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high; NMS management is standard. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a classic triad of fever, muscle rigidity, and elevated CK in a patient on an antipsychotic (clozapine), which is pathognomonic for neuroleptic malignant syndrome (NMS). Key discriminating findings include: (1) antipsychotic exposure, (2) fever + tachycardia (autonomic instability), (3) muscle rigidity (extrapyramidal), (4) elevated CK (rhabdomyolysis), and (5) leukocytosis. Option B correctly identifies NMS and appropriate management with dantrolene (muscle relaxant) and bromocriptine (dopamine agonist), plus supportive care and drug discontinuation. Option A: agranulocytosis presents with infection/neutropenia, not rigidity or elevated CK. Option C: serotonin syndrome typically shows hyperreflexia/clonus rather than lead-pipe rigidity, and CK elevation is less prominent. Option D: catatonia lacks the autonomic instability and marked CK elevation. Option E: clozapine myocarditis presents with chest pain, dyspnea, troponin elevation, and ECG changes—not the neuromuscular syndrome described. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high; NMS management is standard. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-003", "question": "A 65-year-old man undergoes laparoscopic cholecystectomy for acute cholecystitis. Intraoperatively, there is significant bleeding from the cystic artery that is difficult to control. Postoperative imaging reveals a pseudoaneurysm. What is the most appropriate intervention?", "options": ["Endoscopic retrograde cholangiopancreatography with stenting", "Angiographic embolization", "Surgical re-exploration with ligation", "Percutaneous transhepatic cholangiography", "Observation with serial imaging"], "answer": "B", "answer_index": 1, "explanation": "Angiographic embolization is preferred for postoperative pseudoaneurysm to minimize invasiveness and control bleeding effectively. Surgical re-exploration carries higher morbidity, ERCP addresses biliary issues not vascular, PTC is for drainage, and observation risks rupture.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a postoperative pseudoaneurysm of the cystic artery following difficult intraoperative bleeding during cholecystectomy. Key discriminating findings: (1) vascular complication (pseudoaneurysm), (2) postoperative setting, (3) imaging-confirmed diagnosis. The clinical problem is selecting optimal management for a postoperative visceral pseudoaneurysm. Angiographic embolization (B) is the current standard of care for postoperative pseudoaneurysms—minimally invasive, highly effective (>90% success), and lower morbidity than surgery. Surgical re-exploration (C) is reserved for embolization failure or hemodynamic instability not present here. ERCP (A) and PTC (D) address biliary complications, not vascular ones—clearly inferior. Observation (E) is inappropriate given rupture risk (up to 90% mortality if ruptured). The keyed answer aligns with modern interventional radiology practice and hepatobiliary surgery guidelines. No medical inaccuracies detected. The item is logically sound with one defensible best answer matching the key. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a postoperative pseudoaneurysm of the cystic artery following difficult intraoperative bleeding during cholecystectomy. Key discriminating findings: (1) vascular complication (pseudoaneurysm), (2) postoperative setting, (3) imaging-confirmed diagnosis. The clinical problem is selecting optimal management for a postoperative visceral pseudoaneurysm. Angiographic embolization (B) is the current standard of care for postoperative pseudoaneurysms—minimally invasive, highly effective (>90% success), and lower morbidity than surgery. Surgical re-exploration (C) is reserved for embolization failure or hemodynamic instability not present here. ERCP (A) and PTC (D) address biliary complications, not vascular ones—clearly inferior. Observation (E) is inappropriate given rupture risk (up to 90% mortality if ruptured). The keyed answer aligns with modern interventional radiology practice and hepatobiliary surgery guidelines. No medical inaccuracies detected. The item is logically sound with one defensible best answer matching the key. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-004", "question": "A 50-year-old woman with Crohn's disease presents with an enterocutaneous fistula after ileocolic resection. She is hemodynamically stable but has high-output fistula drainage. Which management strategy is most effective for promoting spontaneous closure?", "options": ["Total parenteral nutrition and somatostatin analog", "Immediate surgical closure with bowel resection", "Antibiotic therapy with abscess drainage", "Hyperbaric oxygen therapy", "Fibrin glue injection into the fistula tract"], "answer": "A", "answer_index": 0, "explanation": "TPN and somatostatin analogs reduce gastrointestinal secretions and promote fistula healing in high-output cases. Surgical closure is reserved for failures, antibiotics address infection not closure, hyperbaric oxygen lacks evidence, and fibrin glue is for low-output fistulas.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a postoperative enterocutaneous fistula (ECF) in a Crohn's patient with high-output drainage but hemodynamic stability. Key discriminating findings: (1) high-output fistula, (2) postoperative setting, (3) hemodynamically stable (no sepsis/abscess mentioned). The question asks for the strategy most effective for promoting spontaneous closure. Option A (TPN + somatostatin analog) is the established first-line conservative management for high-output ECF: TPN provides bowel rest and nutritional support while somatostatin analogs (octreotide) reduce GI secretions and fistula output, creating optimal conditions for spontaneous closure. This aligns with standard surgical teaching that 30-40% of ECF close spontaneously with conservative management. Option B (immediate surgery) contradicts the principle that surgery should be delayed 3-6 months to allow spontaneous closure attempts and inflammation resolution. Option C addresses infection/abscess (not mentioned in stem). Option D (hyperbaric oxygen) lacks evidence for ECF. Option E (fibrin glue) is occasionally used for low-output fistulas but not standard for high-output cases. No logical flaws; the keyed answer is uniquely defensible. Medical accuracy is sound per current surgical guidelines. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a postoperative enterocutaneous fistula (ECF) in a Crohn's patient with high-output drainage but hemodynamic stability. Key discriminating findings: (1) high-output fistula, (2) postoperative setting, (3) hemodynamically stable (no sepsis/abscess mentioned). The question asks for the strategy most effective for promoting spontaneous closure. Option A (TPN + somatostatin analog) is the established first-line conservative management for high-output ECF: TPN provides bowel rest and nutritional support while somatostatin analogs (octreotide) reduce GI secretions and fistula output, creating optimal conditions for spontaneous closure. This aligns with standard surgical teaching that 30-40% of ECF close spontaneously with conservative management. Option B (immediate surgery) contradicts the principle that surgery should be delayed 3-6 months to allow spontaneous closure attempts and inflammation resolution. Option C addresses infection/abscess (not mentioned in stem). Option D (hyperbaric oxygen) lacks evidence for ECF. Option E (fibrin glue) is occasionally used for low-output fistulas but not standard for high-output cases. No logical flaws; the keyed answer is uniquely defensible. Medical accuracy is sound per current surgical guidelines. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-005", "question": "A 60-year-old man with diabetes presents with sudden painless vision loss in the right eye. Fundoscopy shows macular edema and neovascularization at the disc. Optical coherence tomography confirms vitreomacular traction. What is the most appropriate initial treatment?", "options": ["Intravitreal anti-VEGF injection", "Panretinal photocoagulation", "Pars plana vitrectomy", "Intravitreal corticosteroid", "Observation with follow-up"], "answer": "C", "answer_index": 2, "explanation": "Pars plana vitrectomy addresses vitreomacular traction in proliferative diabetic retinopathy with macular involvement, relieving traction and allowing further therapy. Anti-VEGF and laser treat neovascularization but not traction, corticosteroids risk complications, and observation may worsen vision.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a diabetic patient with sudden painless vision loss, macular edema, disc neovascularization (indicating proliferative diabetic retinopathy), and vitreomacular traction on OCT. The question asks for \\\"most appropriate initial treatment.\\\" Key issue: Both options A (anti-VEGF) and C (vitrectomy) are defensible as initial therapy. Anti-VEGF is standard first-line for diabetic macular edema with neovascularization and can address both the edema and proliferative disease; it's less invasive and widely used initially. Vitrectomy is appropriate for vitreomacular traction but typically reserved for cases where traction causes significant visual compromise or after medical therapy fails. The stem doesn't specify severity of traction, degree of visual loss, or failure of prior therapy—critical details needed to choose between medical (anti-VEGF) versus surgical (vitrectomy) approaches. Current practice often starts with anti-VEGF for proliferative diabetic retinopathy with macular edema, even with mild traction. Medical accuracy: Both treatments are medically sound but for different clinical scenarios. Minimal fix: Specify \\\"severe vitreomacular traction with tractional retinal detachment\\\" or \\\"failed anti-VEGF therapy\\\" to make vitrectomy the clear best answer.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a diabetic patient with sudden painless vision loss, macular edema, disc neovascularization (indicating proliferative diabetic retinopathy), and vitreomacular traction on OCT. The question asks for \"most appropriate initial treatment.\" Key issue: Both options A (anti-VEGF) and C (vitrectomy) are defensible as initial therapy. Anti-VEGF is standard first-line for diabetic macular edema with neovascularization and can address both the edema and proliferative disease; it's less invasive and widely used initially. Vitrectomy is appropriate for vitreomacular traction but typically reserved for cases where traction causes significant visual compromise or after medical therapy fails. The stem doesn't specify severity of traction, degree of visual loss, or failure of prior therapy—critical details needed to choose between medical (anti-VEGF) versus surgical (vitrectomy) approaches. Current practice often starts with anti-VEGF for proliferative diabetic retinopathy with macular edema, even with mild traction. Medical accuracy: Both treatments are medically sound but for different clinical scenarios. Minimal fix: Specify \"severe vitreomacular traction with tractional retinal detachment\" or \"failed anti-VEGF therapy\" to make vitrectomy the clear best answer.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-006", "question": "A 25-year-old athlete sustains a tibial plateau fracture with associated meniscal tear and ACL disruption. Intraoperative findings include a depressed lateral plateau fragment. What is the optimal surgical approach to restore joint congruity?", "options": ["External fixation with delayed internal fixation", "Arthroscopic-assisted reduction and internal fixation", "Open reduction with bone grafting and buttress plating", "Total knee arthroplasty", "Nonoperative management with bracing"], "answer": "C", "answer_index": 2, "explanation": "Open reduction with bone grafting and buttress plating restores articular surface in complex tibial plateau fractures with depression. Arthroscopic assistance is for simpler cases, external fixation is temporary, arthroplasty is for older patients, and nonoperative risks malunion.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Orthopedic Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 25-year-old athlete with a complex tibial plateau fracture featuring a depressed lateral plateau fragment, meniscal tear, and ACL disruption. Key discriminating findings: (1) young, active patient requiring anatomic restoration, (2) depressed articular fragment requiring elevation, (3) complex injury pattern with associated soft-tissue injuries. The keyed answer (C) is defensible because depressed plateau fragments require open reduction to elevate the articular surface, bone grafting to fill the metaphyseal void created by elevation, and buttress plating for structural support—standard treatment for Schatzker II-III fractures with depression. Alternative analysis: (A) External fixation is temporizing, not definitive; (B) Arthroscopic assistance works for minimal depression (<2mm) without significant comminution, inadequate here; (D) TKA inappropriate for young patients with acute trauma; (E) Nonoperative management risks post-traumatic arthritis with articular incongruity. The item is logically valid with one clearly superior answer. Medical accuracy is sound, reflecting current orthopedic trauma principles. No fix needed.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 25-year-old athlete with a complex tibial plateau fracture featuring a depressed lateral plateau fragment, meniscal tear, and ACL disruption. Key discriminating findings: (1) young, active patient requiring anatomic restoration, (2) depressed articular fragment requiring elevation, (3) complex injury pattern with associated soft-tissue injuries. The keyed answer (C) is defensible because depressed plateau fragments require open reduction to elevate the articular surface, bone grafting to fill the metaphyseal void created by elevation, and buttress plating for structural support—standard treatment for Schatzker II-III fractures with depression. Alternative analysis: (A) External fixation is temporizing, not definitive; (B) Arthroscopic assistance works for minimal depression (<2mm) without significant comminution, inadequate here; (D) TKA inappropriate for young patients with acute trauma; (E) Nonoperative management risks post-traumatic arthritis with articular incongruity. The item is logically valid with one clearly superior answer. Medical accuracy is sound, reflecting current orthopedic trauma principles. No fix needed.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-007", "question": "A 55-year-old woman with multiple sclerosis presents with progressive spastic paraparesis and urinary incontinence. MRI shows a syrinx from C4 to T2 without Chiari malformation. What is the most likely underlying mechanism, and appropriate management?", "options": ["Post-traumatic syrinx; syringoperitoneal shunting", "Idiopathic syringomyelia; conservative monitoring", "Tumoral syrinx; biopsy and resection", "Inflammatory syrinx due to MS; high-dose steroids", "Arachnoiditis-related; laminectomy with adhesiolysis"], "answer": "A", "answer_index": 0, "explanation": "Post-traumatic syrinx in MS context likely from prior demyelination scars disrupting CSF flow, managed with shunting to prevent progression. Idiopathic lacks MS history, tumoral requires mass evidence, steroids treat acute flares not syrinx, adhesiolysis is for specific scarring.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. The stem describes a patient with established MS presenting with a syrinx from C4-T2 without Chiari malformation. Key discriminating findings: (1) known MS diagnosis, (2) progressive spastic paraparesis and urinary incontinence, (3) syrinx without Chiari. The question asks for mechanism AND management. Option D (inflammatory syrinx due to MS with steroids) is problematic because steroids don't treat syrinx formation. Option A (post-traumatic with shunting) assumes prior trauma not mentioned in the stem. The most defensible answer is actually C or E: syrinx in MS patients can result from inflammatory arachnoiditis or tumefactive demyelinating lesions causing CSF flow obstruction. The rationale's claim that 'post-traumatic syrinx in MS context likely from prior demyelination scars' conflates inflammatory/demyelinating pathology with trauma. Without explicit trauma history, calling this 'post-traumatic' is inaccurate. The stem is underspecified regarding prior trauma, tumor presence, or arachnoiditis evidence, making definitive mechanism determination impossible. Main medical issue: the keyed answer mislabels inflammatory/demyelinating pathology as 'post-traumatic.' Minimal fix: add explicit trauma history to justify option A, or change key to option C/E with appropriate imaging findings.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the keyed answer is not the best answer. The stem describes a patient with established MS presenting with a syrinx from C4-T2 without Chiari malformation. Key discriminating findings: (1) known MS diagnosis, (2) progressive spastic paraparesis and urinary incontinence, (3) syrinx without Chiari. The question asks for mechanism AND management. Option D (inflammatory syrinx due to MS with steroids) is problematic because steroids don't treat syrinx formation. Option A (post-traumatic with shunting) assumes prior trauma not mentioned in the stem. The most defensible answer is actually C or E: syrinx in MS patients can result from inflammatory arachnoiditis or tumefactive demyelinating lesions causing CSF flow obstruction. The rationale's claim that 'post-traumatic syrinx in MS context likely from prior demyelination scars' conflates inflammatory/demyelinating pathology with trauma. Without explicit trauma history, calling this 'post-traumatic' is inaccurate. The stem is underspecified regarding prior trauma, tumor presence, or arachnoiditis evidence, making definitive mechanism determination impossible. Main medical issue: the keyed answer mislabels inflammatory/demyelinating pathology as 'post-traumatic.' Minimal fix: add explicit trauma history to justify option A, or change key to option C/E with appropriate imaging findings.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-008", "question": "A 40-year-old man with epilepsy on carbamazepine develops diplopia, ataxia, and nystagmus. Serum levels are therapeutic, but free fraction is elevated. What is the most likely cause, and adjustment needed?", "options": ["Hyponatremia; restrict fluids", "Drug interaction with protein binding; reduce dose", "Autoinduction; increase dose", "Hepatic failure; switch to alternative", "Renal impairment; hemodialysis"], "answer": "B", "answer_index": 1, "explanation": "Elevated free carbamazepine due to hypoalbuminemia or displacement increases toxicity despite therapeutic total levels, requiring dose reduction. Hyponatremia causes different symptoms, autoinduction lowers levels, hepatic failure elevates total levels, renal issues don't directly affect binding.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic carbamazepine toxicity (diplopia, ataxia, nystagmus) with therapeutic total serum levels but elevated free fraction—a scenario indicating altered protein binding. Key discriminating findings: (1) toxicity symptoms present, (2) total levels therapeutic, (3) free fraction elevated. This constellation points to decreased protein binding (hypoalbuminemia or drug displacement), causing increased unbound active drug despite normal total levels. Option B correctly identifies protein-binding alteration and appropriate management (dose reduction). Option A (hyponatremia): carbamazepine causes SIADH/hyponatremia, but this presents with confusion/seizures, not the triad described; fluid restriction wouldn't address elevated free drug. Option C (autoinduction): lowers total levels over weeks, opposite of therapeutic levels. Option D (hepatic failure): would elevate total levels and cause different symptoms. Option E (renal impairment): carbamazepine is hepatically metabolized; renal issues don't explain protein-binding changes or warrant hemodialysis. Medical accuracy: sound—free drug monitoring is critical when total levels are misleading. Minimal fix: none needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic carbamazepine toxicity (diplopia, ataxia, nystagmus) with therapeutic total serum levels but elevated free fraction—a scenario indicating altered protein binding. Key discriminating findings: (1) toxicity symptoms present, (2) total levels therapeutic, (3) free fraction elevated. This constellation points to decreased protein binding (hypoalbuminemia or drug displacement), causing increased unbound active drug despite normal total levels. Option B correctly identifies protein-binding alteration and appropriate management (dose reduction). Option A (hyponatremia): carbamazepine causes SIADH/hyponatremia, but this presents with confusion/seizures, not the triad described; fluid restriction wouldn't address elevated free drug. Option C (autoinduction): lowers total levels over weeks, opposite of therapeutic levels. Option D (hepatic failure): would elevate total levels and cause different symptoms. Option E (renal impairment): carbamazepine is hepatically metabolized; renal issues don't explain protein-binding changes or warrant hemodialysis. Medical accuracy: sound—free drug monitoring is critical when total levels are misleading. Minimal fix: none needed; item is logically valid and medically accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-009", "question": "A 35-year-old woman presents with erythematous plaques on the trunk and positive Darier's sign. Biopsy shows mast cell infiltration. Systemic symptoms include flushing and diarrhea. What is the most appropriate long-term management?", "options": ["Oral cromolyn sodium", "Imatinib therapy", "Omalizumab injections", "Bone marrow transplantation", "Interferon-alpha"], "answer": "A", "answer_index": 0, "explanation": "Oral cromolyn stabilizes mast cells in cutaneous mastocytosis with systemic features, reducing mediator release. Imatinib is for KIT mutations not present here, omalizumab for allergic components, transplantation for aggressive forms, interferon for indolent systemic mastocytosis.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Dermatology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a patient with cutaneous mastocytosis (erythematous plaques, positive Darier's sign, mast cell infiltration on biopsy) plus systemic symptoms (flushing, diarrhea). The critical missing detail is whether this represents cutaneous mastocytosis with systemic mediator symptoms versus true systemic mastocytosis (SM). The stem lacks: (1) tryptase level, (2) bone marrow findings, (3) organomegaly/cytopenias, (4) KIT mutation status. Without these, multiple management approaches are defensible. Oral cromolyn (key A) treats GI symptoms from mast cell mediator release and is reasonable for cutaneous disease with GI symptoms. However, if this is indolent SM (which systemic symptoms suggest), interferon-alpha (E) is established therapy per WHO/NCCN guidelines for symptomatic indolent SM. Imatinib (B) requires known KIT mutation data (absent here). The explanation dismisses imatinib for 'KIT mutations not present' but the stem never states mutation status—this is an unstated assumption. The distinction between cutaneous mastocytosis with mediator symptoms versus true SM is critical for management but cannot be determined from the vignette. Minimal fix: Add 'Serum tryptase normal, no organomegaly' to clearly indicate cutaneous disease, making cromolyn the unambiguous best answer.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a patient with cutaneous mastocytosis (erythematous plaques, positive Darier's sign, mast cell infiltration on biopsy) plus systemic symptoms (flushing, diarrhea). The critical missing detail is whether this represents cutaneous mastocytosis with systemic mediator symptoms versus true systemic mastocytosis (SM). The stem lacks: (1) tryptase level, (2) bone marrow findings, (3) organomegaly/cytopenias, (4) KIT mutation status. Without these, multiple management approaches are defensible. Oral cromolyn (key A) treats GI symptoms from mast cell mediator release and is reasonable for cutaneous disease with GI symptoms. However, if this is indolent SM (which systemic symptoms suggest), interferon-alpha (E) is established therapy per WHO/NCCN guidelines for symptomatic indolent SM. Imatinib (B) requires known KIT mutation data (absent here). The explanation dismisses imatinib for 'KIT mutations not present' but the stem never states mutation status—this is an unstated assumption. The distinction between cutaneous mastocytosis with mediator symptoms versus true SM is critical for management but cannot be determined from the vignette. Minimal fix: Add 'Serum tryptase normal, no organomegaly' to clearly indicate cutaneous disease, making cromolyn the unambiguous best answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-010", "question": "A 55-year-old man with prostate cancer on androgen deprivation therapy develops urinary retention. Cystoscopy reveals bladder neck contracture. What is the most effective definitive treatment?", "options": ["Transurethral incision of the bladder neck", "Suprapubic catheter placement", "Alpha-blocker therapy", "Intravesical botulinum toxin injection", "Urethral dilation with sounds"], "answer": "A", "answer_index": 0, "explanation": "Transurethral incision relieves bladder neck contracture post-ADT, providing durable relief. Suprapubic catheter is palliative, alpha-blockers ineffective for scarring, botulinum for detrusor issues, dilation temporary and recurrent.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 55-year-old man on androgen deprivation therapy (ADT) for prostate cancer who develops urinary retention, with cystoscopy confirming bladder neck contracture. The question asks for the most effective definitive treatment. Key discriminating findings: (1) confirmed bladder neck contracture on cystoscopy, (2) context of ADT (known risk factor for bladder neck contracture). Transurethral incision of the bladder neck (TURBN) is the established definitive surgical treatment for bladder neck contracture, providing durable relief by incising the fibrotic tissue. Option B (suprapubic catheter) is palliative drainage, not definitive. Option C (alpha-blockers) treats functional obstruction but not fixed anatomic scarring. Option D (botulinum toxin) addresses detrusor overactivity, not bladder neck obstruction. Option E (urethral dilation) provides only temporary relief with high recurrence rates for contractures. The keyed answer aligns with standard urologic practice. Medical accuracy: The item correctly identifies TURBN as definitive treatment for bladder neck contracture, consistent with urologic guidelines. No medical inaccuracies detected. The vignette provides sufficient detail to select a unique best answer. No fix needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 55-year-old man on androgen deprivation therapy (ADT) for prostate cancer who develops urinary retention, with cystoscopy confirming bladder neck contracture. The question asks for the most effective definitive treatment. Key discriminating findings: (1) confirmed bladder neck contracture on cystoscopy, (2) context of ADT (known risk factor for bladder neck contracture). Transurethral incision of the bladder neck (TURBN) is the established definitive surgical treatment for bladder neck contracture, providing durable relief by incising the fibrotic tissue. Option B (suprapubic catheter) is palliative drainage, not definitive. Option C (alpha-blockers) treats functional obstruction but not fixed anatomic scarring. Option D (botulinum toxin) addresses detrusor overactivity, not bladder neck obstruction. Option E (urethral dilation) provides only temporary relief with high recurrence rates for contractures. The keyed answer aligns with standard urologic practice. Medical accuracy: The item correctly identifies TURBN as definitive treatment for bladder neck contracture, consistent with urologic guidelines. No medical inaccuracies detected. The vignette provides sufficient detail to select a unique best answer. No fix needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-011", "question": "A 28-year-old pregnant woman at 32 weeks gestation with major depressive disorder relapses after stopping sertraline. She has suicidal ideation. What is the most appropriate pharmacologic intervention?", "options": ["Restart sertraline at previous dose", "Initiate electroconvulsive therapy", "Start bupropion extended-release", "Prescribe mirtazapine", "Use transcranial magnetic stimulation"], "answer": "B", "answer_index": 1, "explanation": "ECT is safe and effective for severe depression in pregnancy with suicidality, avoiding fetal medication exposure. Sertraline risks neonatal adaptation syndrome, bupropion seizure risk, mirtazapine sedation, TMS less evidence in acute suicidality.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – sertraline (A) is the correct best answer, not ECT (B). The stem describes a pregnant woman at 32 weeks with MDD relapse and suicidal ideation after stopping sertraline. Key discriminating findings: (1) previously responsive to sertraline, (2) relapse after discontinuation, (3) suicidal ideation present but no indication of imminent danger, psychosis, or treatment refusal that would mandate ECT. Standard psychiatric practice for pregnancy: restart previously effective medication (sertraline is FDA pregnancy category C, well-studied SSRI in pregnancy) as first-line for relapse. ECT is reserved for severe, refractory depression, catatonia, or when immediate response needed and medications have failed/are contraindicated. The presence of suicidal ideation alone does not mandate ECT over restarting effective pharmacotherapy. The rationale incorrectly elevates ECT above medication restart and overstates risks (neonatal adaptation syndrome is typically mild/self-limited). Main logical issue: the keyed answer (B) represents second-line treatment when first-line (A) is available and appropriate. Main medical accuracy issue: ECT indication criteria misapplied; suicidal ideation in context of known medication response favors restarting that medication. Minimal fix: change key to A, or add stem details indicating sertraline failure/contraindication or severe/psychotic features requiring ECT.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – sertraline (A) is the correct best answer, not ECT (B). The stem describes a pregnant woman at 32 weeks with MDD relapse and suicidal ideation after stopping sertraline. Key discriminating findings: (1) previously responsive to sertraline, (2) relapse after discontinuation, (3) suicidal ideation present but no indication of imminent danger, psychosis, or treatment refusal that would mandate ECT. Standard psychiatric practice for pregnancy: restart previously effective medication (sertraline is FDA pregnancy category C, well-studied SSRI in pregnancy) as first-line for relapse. ECT is reserved for severe, refractory depression, catatonia, or when immediate response needed and medications have failed/are contraindicated. The presence of suicidal ideation alone does not mandate ECT over restarting effective pharmacotherapy. The rationale incorrectly elevates ECT above medication restart and overstates risks (neonatal adaptation syndrome is typically mild/self-limited). Main logical issue: the keyed answer (B) represents second-line treatment when first-line (A) is available and appropriate. Main medical accuracy issue: ECT indication criteria misapplied; suicidal ideation in context of known medication response favors restarting that medication. Minimal fix: change key to A, or add stem details indicating sertraline failure/contraindication or severe/psychotic features requiring ECT.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-012", "question": "A 60-year-old man with alcohol use disorder presents with confabulation, ophthalmoplegia, and ataxia. MRI shows mamillary body atrophy. What is the underlying deficiency, and specific treatment?", "options": ["Vitamin B12; intramuscular cyanocobalamin", "Thiamine; intravenous thiamine", "Folate; oral folic acid", "Vitamin E; alpha-tocopherol", "Magnesium; intravenous magnesium sulfate"], "answer": "B", "answer_index": 1, "explanation": "Thiamine deficiency causes Wernicke-Korsakoff syndrome, treated urgently with IV thiamine to prevent irreversible damage. B12 deficiency causes subacute combined degeneration, folate anemia, vitamin E ataxia without confabulation, magnesium tremors not ophthalmoplegia.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a classic triad of Wernicke-Korsakoff syndrome in an alcoholic patient: confabulation (Korsakoff psychosis), ophthalmoplegia, and ataxia, with MRI showing mamillary body atrophy—a pathognomonic finding for chronic thiamine deficiency. Key discriminating findings: (1) alcohol use disorder (major risk factor for thiamine deficiency), (2) classic triad of symptoms, (3) mamillary body atrophy on imaging. Option B (thiamine; IV thiamine) is the unambiguous best answer, as Wernicke-Korsakoff syndrome requires urgent IV thiamine to prevent irreversible neurological damage. Alternative assessment: A (B12) causes subacute combined degeneration with posterior column/corticospinal findings, not this triad or mamillary atrophy; C (folate) causes megaloblastic anemia without these neurological findings; D (vitamin E) causes ataxia but not ophthalmoplegia or confabulation; E (magnesium) can cause tremor/tetany but not this syndrome. The keyed answer is medically accurate and consistent with standard emergency management. No logical issues; all stem clues converge on a single diagnosis. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a classic triad of Wernicke-Korsakoff syndrome in an alcoholic patient: confabulation (Korsakoff psychosis), ophthalmoplegia, and ataxia, with MRI showing mamillary body atrophy—a pathognomonic finding for chronic thiamine deficiency. Key discriminating findings: (1) alcohol use disorder (major risk factor for thiamine deficiency), (2) classic triad of symptoms, (3) mamillary body atrophy on imaging. Option B (thiamine; IV thiamine) is the unambiguous best answer, as Wernicke-Korsakoff syndrome requires urgent IV thiamine to prevent irreversible neurological damage. Alternative assessment: A (B12) causes subacute combined degeneration with posterior column/corticospinal findings, not this triad or mamillary atrophy; C (folate) causes megaloblastic anemia without these neurological findings; D (vitamin E) causes ataxia but not ophthalmoplegia or confabulation; E (magnesium) can cause tremor/tetany but not this syndrome. The keyed answer is medically accurate and consistent with standard emergency management. No logical issues; all stem clues converge on a single diagnosis. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-013", "question": "A 42-year-old woman undergoes Whipple procedure for pancreatic adenocarcinoma. Postoperatively, she develops delayed gastric emptying with high nasogastric output. What is the most effective prokinetic agent?", "options": ["Metoclopramide intravenously", "Erythromycin orally", "Domperidone orally", "Prucalopride", "Octreotide subcutaneously"], "answer": "B", "answer_index": 1, "explanation": "Erythromycin acts as a motilin agonist to enhance gastric motility in post-Whipple delayed emptying. Metoclopramide risks tardive dyskinesia, domperidone cardiac issues, prucalopride for colon, octreotide inhibits motility.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – metoclopramide IV is the correct best answer, not erythromycin orally. Clinical problem: Post-Whipple delayed gastric emptying (DGE) requiring prokinetic therapy. Key discriminating findings: postoperative setting with high NG output after pancreaticoduodenectomy. Most likely need: effective prokinetic agent for upper GI motility. The keyed answer (erythromycin orally) has significant limitations: oral administration is problematic with high NG output and gastroparesis; erythromycin's prokinetic effect shows rapid tachyphylaxis (often within 2-4 weeks); IV formulation would be preferred but oral route specified. Metoclopramide IV (option A) is actually the most appropriate choice: IV route bypasses absorption issues, it's first-line for postoperative gastroparesis, and while tardive dyskinesia is a concern with chronic use, short-term postoperative use is standard practice. The rationale's dismissal of metoclopramide based solely on tardive dyskinesia risk is excessive for acute postoperative management. Domperidone has limited US availability and cardiac concerns. Prucalopride targets lower GI. Octreotide inhibits motility. Medical accuracy issue: overstating tardive dyskinesia risk in acute setting while understating erythromycin's tachyphylaxis and oral route impracticality. Minimal fix: Change key to A (metoclopramide IV) or specify IV erythromycin if that were the intended answer.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – metoclopramide IV is the correct best answer, not erythromycin orally. Clinical problem: Post-Whipple delayed gastric emptying (DGE) requiring prokinetic therapy. Key discriminating findings: postoperative setting with high NG output after pancreaticoduodenectomy. Most likely need: effective prokinetic agent for upper GI motility. The keyed answer (erythromycin orally) has significant limitations: oral administration is problematic with high NG output and gastroparesis; erythromycin's prokinetic effect shows rapid tachyphylaxis (often within 2-4 weeks); IV formulation would be preferred but oral route specified. Metoclopramide IV (option A) is actually the most appropriate choice: IV route bypasses absorption issues, it's first-line for postoperative gastroparesis, and while tardive dyskinesia is a concern with chronic use, short-term postoperative use is standard practice. The rationale's dismissal of metoclopramide based solely on tardive dyskinesia risk is excessive for acute postoperative management. Domperidone has limited US availability and cardiac concerns. Prucalopride targets lower GI. Octreotide inhibits motility. Medical accuracy issue: overstating tardive dyskinesia risk in acute setting while understating erythromycin's tachyphylaxis and oral route impracticality. Minimal fix: Change key to A (metoclopramide IV) or specify IV erythromycin if that were the intended answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-014", "question": "A 70-year-old man with diverticulitis undergoes Hartmann's procedure. Six months later, he presents for reversal but has severe cardiac comorbidity. What is the safest reversal technique?", "options": ["Laparoscopic colostomy reversal with anastomosis", "Open reversal with protective ileostomy", "Endoscopic stenting of the rectal stump", "Percutaneous endoscopic colostomy", "Continued observation"], "answer": "A", "answer_index": 0, "explanation": "Laparoscopic approach minimizes morbidity in high-risk patients for Hartmann's reversal. Open with ileostomy adds procedures, stenting not for reversal, PEC for constipation, observation avoids surgery but maintains stoma.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 70-year-old man with severe cardiac comorbidity seeking Hartmann's reversal. Key discriminating findings: (1) post-Hartmann's anatomy requiring reconnection, (2) severe cardiac comorbidity necessitating minimally invasive approach. The keyed answer (A) laparoscopic reversal is defensible as the safest option because it achieves the therapeutic goal (restoring bowel continuity) while minimizing physiologic stress in a high-risk cardiac patient. Option B (open with protective ileostomy) adds surgical trauma and an additional procedure, increasing cardiac risk. Option C (endoscopic stenting) is not a standard reversal technique for Hartmann's. Option D (PEC) does not reverse the Hartmann's. Option E (observation) avoids surgery but leaves the patient with a permanent stoma when reversal is desired and feasible. The item is logically valid: one best answer is defensible, the key matches it, and no contradictions exist. Medical accuracy is sound: laparoscopic Hartmann's reversal is established as safer than open in high-risk patients per contemporary literature. No fix needed; the item appropriately tests knowledge of minimally invasive approaches in high-risk surgical candidates.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 70-year-old man with severe cardiac comorbidity seeking Hartmann's reversal. Key discriminating findings: (1) post-Hartmann's anatomy requiring reconnection, (2) severe cardiac comorbidity necessitating minimally invasive approach. The keyed answer (A) laparoscopic reversal is defensible as the safest option because it achieves the therapeutic goal (restoring bowel continuity) while minimizing physiologic stress in a high-risk cardiac patient. Option B (open with protective ileostomy) adds surgical trauma and an additional procedure, increasing cardiac risk. Option C (endoscopic stenting) is not a standard reversal technique for Hartmann's. Option D (PEC) does not reverse the Hartmann's. Option E (observation) avoids surgery but leaves the patient with a permanent stoma when reversal is desired and feasible. The item is logically valid: one best answer is defensible, the key matches it, and no contradictions exist. Medical accuracy is sound: laparoscopic Hartmann's reversal is established as safer than open in high-risk patients per contemporary literature. No fix needed; the item appropriately tests knowledge of minimally invasive approaches in high-risk surgical candidates.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-015", "question": "A 45-year-old woman with rheumatoid arthritis on methotrexate develops corneal melt and peripheral ulcerative keratitis. What is the most appropriate immunosuppressive therapy adjustment?", "options": ["Add infliximab infusion", "Switch to rituximab", "Initiate cyclophosphamide", "Topical cyclosporine", "Systemic corticosteroids with azathioprine"], "answer": "C", "answer_index": 2, "explanation": "Cyclophosphamide is used for severe ocular manifestations in rheumatoid vasculitis like corneal melt. Infliximab for joints, rituximab B-cell depletion insufficient alone, topical for surface, steroids with azathioprine less potent for melt.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 45-year-old woman with RA on methotrexate who develops corneal melt and peripheral ulcerative keratitis (PUK)—a severe, vision-threatening manifestation of rheumatoid vasculitis requiring aggressive systemic immunosuppression. Key discriminating findings: established RA, current methotrexate (inadequate control), corneal melt/PUK (necrotizing scleritis spectrum). Corneal melt in RA represents necrotizing inflammation from immune-complex vasculitis; standard management requires potent systemic immunosuppression to prevent perforation and vision loss. Cyclophosphamide (C) is the established first-line agent for severe RA-associated ocular vasculitis and corneal melt, supported by rheumatology and ophthalmology literature. Alternative analysis: (A) Infliximab—effective for RA joints but insufficient monotherapy for acute corneal melt; (B) Rituximab—increasingly used but traditionally second-line to cyclophosphamide for acute severe disease; (D) Topical cyclosporine—inadequate for systemic vasculitis-driven melt; (E) Corticosteroids+azathioprine—less potent than cyclophosphamide for necrotizing disease. The keyed answer is medically sound and uniquely best for this emergency. No logical flaws or missing critical details. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 45-year-old woman with RA on methotrexate who develops corneal melt and peripheral ulcerative keratitis (PUK)—a severe, vision-threatening manifestation of rheumatoid vasculitis requiring aggressive systemic immunosuppression. Key discriminating findings: established RA, current methotrexate (inadequate control), corneal melt/PUK (necrotizing scleritis spectrum). Corneal melt in RA represents necrotizing inflammation from immune-complex vasculitis; standard management requires potent systemic immunosuppression to prevent perforation and vision loss. Cyclophosphamide (C) is the established first-line agent for severe RA-associated ocular vasculitis and corneal melt, supported by rheumatology and ophthalmology literature. Alternative analysis: (A) Infliximab—effective for RA joints but insufficient monotherapy for acute corneal melt; (B) Rituximab—increasingly used but traditionally second-line to cyclophosphamide for acute severe disease; (D) Topical cyclosporine—inadequate for systemic vasculitis-driven melt; (E) Corticosteroids+azathioprine—less potent than cyclophosphamide for necrotizing disease. The keyed answer is medically sound and uniquely best for this emergency. No logical flaws or missing critical details. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-016", "question": "A 35-year-old man sustains a humeral shaft fracture with radial nerve palsy. Exploration shows nerve entrapment in the fracture site. What is the optimal management of the nerve injury?", "options": ["Immediate nerve grafting", "Neurolysis and fracture fixation", "Nerve transfer from triceps branch", "Tendon transfer for wrist extension", "Observation with serial EMG"], "answer": "B", "answer_index": 1, "explanation": "Neurolysis frees the entrapped radial nerve during fracture fixation, allowing potential recovery. Grafting for transection, transfer for irreparable, tendon for chronic, observation misses surgical window.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Orthopedic Surgery", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes a humeral shaft fracture with radial nerve palsy where exploration reveals nerve entrapment (not transection) in the fracture site. Key discriminating findings: (1) nerve is entrapped but intact, (2) surgical exploration already performed, (3) acute setting requiring fracture fixation. The clinical problem asks for optimal management of an entrapped-but-intact nerve discovered intraoperatively. Option B (neurolysis and fracture fixation) is the correct best answer: neurolysis releases the entrapped nerve from surrounding scar/bone fragments while fracture fixation stabilizes the injury, addressing both pathologies simultaneously and maximizing recovery potential. Option A (immediate grafting) is for nerve transection, not entrapment. Option C (nerve transfer) is reserved for irreparable nerve injuries after failed recovery. Option D (tendon transfer) addresses chronic deficits, not acute nerve entrapment. Option E (observation) is inappropriate when entrapment is confirmed surgically and requires release. The item is logically valid with one defensible best answer matching the key. Medical accuracy is sound: neurolysis for entrapped-but-intact nerves is standard neurosurgical practice. No fix needed; item functions as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a humeral shaft fracture with radial nerve palsy where exploration reveals nerve entrapment (not transection) in the fracture site. Key discriminating findings: (1) nerve is entrapped but intact, (2) surgical exploration already performed, (3) acute setting requiring fracture fixation. The clinical problem asks for optimal management of an entrapped-but-intact nerve discovered intraoperatively. Option B (neurolysis and fracture fixation) is the correct best answer: neurolysis releases the entrapped nerve from surrounding scar/bone fragments while fracture fixation stabilizes the injury, addressing both pathologies simultaneously and maximizing recovery potential. Option A (immediate grafting) is for nerve transection, not entrapment. Option C (nerve transfer) is reserved for irreparable nerve injuries after failed recovery. Option D (tendon transfer) addresses chronic deficits, not acute nerve entrapment. Option E (observation) is inappropriate when entrapment is confirmed surgically and requires release. The item is logically valid with one defensible best answer matching the key. Medical accuracy is sound: neurolysis for entrapped-but-intact nerves is standard neurosurgical practice. No fix needed; item functions as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-017", "question": "A 65-year-old man with Parkinson's disease develops impulse control disorder on pramipexole. He also has motor fluctuations. What is the most appropriate medication adjustment?", "options": ["Switch to rotigotine patch", "Add entacapone", "Initiate deep brain stimulation evaluation", "Start apomorphine subcutaneous", "Convert to levodopa-benserazide"], "answer": "D", "answer_index": 3, "explanation": "Apomorphine provides rapid relief for fluctuations and may reduce dopamine agonist dose, mitigating ICD. Rotigotine similar risk, entacapone extends levodopa, DBS for advanced, levodopa increases dyskinesia risk.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - E is the best answer. The stem describes a patient with Parkinson's disease on pramipexole (dopamine agonist) who developed impulse control disorder (ICD) AND has motor fluctuations. Key discriminating findings: (1) ICD on dopamine agonist, (2) motor fluctuations requiring continued treatment. The clinical problem is managing both issues simultaneously. For ICD on dopamine agonists, standard management is to reduce/discontinue the agonist. Option E (convert to levodopa-benserazide) directly addresses both problems: eliminates the ICD-causing agonist while maintaining motor control with levodopa. Option D (apomorphine) is a rescue therapy for OFF episodes but doesn't address the root cause (pramipexole-induced ICD) and requires continued agonist use. The rationale incorrectly suggests apomorphine 'may reduce dopamine agonist dose' - this is not its primary indication. Options A (rotigotine) perpetuates ICD risk as another agonist. Option B (entacapone) augments levodopa without addressing the agonist. Option C (DBS) is premature without medication optimization. Main logical issue: the keyed answer treats fluctuations but ignores the primary problem (ICD requiring agonist discontinuation). Minimal fix: Change key to E or reframe question to focus only on fluctuation management without ICD.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - E is the best answer. The stem describes a patient with Parkinson's disease on pramipexole (dopamine agonist) who developed impulse control disorder (ICD) AND has motor fluctuations. Key discriminating findings: (1) ICD on dopamine agonist, (2) motor fluctuations requiring continued treatment. The clinical problem is managing both issues simultaneously. For ICD on dopamine agonists, standard management is to reduce/discontinue the agonist. Option E (convert to levodopa-benserazide) directly addresses both problems: eliminates the ICD-causing agonist while maintaining motor control with levodopa. Option D (apomorphine) is a rescue therapy for OFF episodes but doesn't address the root cause (pramipexole-induced ICD) and requires continued agonist use. The rationale incorrectly suggests apomorphine 'may reduce dopamine agonist dose' - this is not its primary indication. Options A (rotigotine) perpetuates ICD risk as another agonist. Option B (entacapone) augments levodopa without addressing the agonist. Option C (DBS) is premature without medication optimization. Main logical issue: the keyed answer treats fluctuations but ignores the primary problem (ICD requiring agonist discontinuation). Minimal fix: Change key to E or reframe question to focus only on fluctuation management without ICD.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-018", "question": "A 50-year-old woman with migraine presents with hemiplegic episodes and family history of similar symptoms. Genetic testing reveals CACNA1A mutation. What is the most effective prophylactic treatment?", "options": ["Verapamil extended-release", "Topiramate", "Propranolol", "Amitriptyline", "Valproate"], "answer": "A", "answer_index": 0, "explanation": "Verapamil is preferred for familial hemiplegic migraine due to calcium channel involvement. Topiramate and valproate for common migraine, propranolol beta-blockade, amitriptyline for tension overlap.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes familial hemiplegic migraine (FHM) type 1, indicated by hemiplegic episodes, family history, and CACNA1A mutation (encoding P/Q-type calcium channels). Key discriminating findings: hemiplegic migraine, positive family history, CACNA1A mutation. Verapamil (calcium channel blocker) is the most rational prophylactic choice given the calcium channelopathy pathophysiology. The keyed answer (A) is defensible as best. Alternative assessment: (B) Topiramate—standard migraine prophylaxis but not specifically targeting the calcium channel defect; (C) Propranolol—beta-blocker, may worsen hemiplegic migraine or be less effective in FHM; (D) Amitriptyline—tricyclic, not first-line for FHM; (E) Valproate—effective for migraine but not specifically addressing calcium channel pathology. The item is logically valid with one defensible best answer matching the key. Medical accuracy: While evidence for FHM prophylaxis is limited, verapamil's mechanism targeting calcium channels makes it the most physiologically rational choice. Some sources suggest acetazolamide or flunarizine, but among the options provided, verapamil is most defensible. No major medical inaccuracies. Minimal fix: None required; item is valid and accurate.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes familial hemiplegic migraine (FHM) type 1, indicated by hemiplegic episodes, family history, and CACNA1A mutation (encoding P/Q-type calcium channels). Key discriminating findings: hemiplegic migraine, positive family history, CACNA1A mutation. Verapamil (calcium channel blocker) is the most rational prophylactic choice given the calcium channelopathy pathophysiology. The keyed answer (A) is defensible as best. Alternative assessment: (B) Topiramate—standard migraine prophylaxis but not specifically targeting the calcium channel defect; (C) Propranolol—beta-blocker, may worsen hemiplegic migraine or be less effective in FHM; (D) Amitriptyline—tricyclic, not first-line for FHM; (E) Valproate—effective for migraine but not specifically addressing calcium channel pathology. The item is logically valid with one defensible best answer matching the key. Medical accuracy: While evidence for FHM prophylaxis is limited, verapamil's mechanism targeting calcium channels makes it the most physiologically rational choice. Some sources suggest acetazolamide or flunarizine, but among the options provided, verapamil is most defensible. No major medical inaccuracies. Minimal fix: None required; item is valid and accurate.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-019", "question": "A 40-year-old man with HIV on antiretroviral therapy develops violaceous plaques on the legs. Biopsy shows spindle cells and HHV-8 positivity. What is the most appropriate systemic therapy?", "options": ["Liposomal doxorubicin", "Interferon-alpha", "Thalidomide", "Sirolimus", "Rituximab"], "answer": "D", "answer_index": 3, "explanation": "Sirolimus inhibits mTOR in AIDS-related Kaposi sarcoma, reducing progression in immunocompromised patients. Doxorubicin for advanced, interferon immunomodulation, thalidomide anti-angiogenic but toxic, rituximab for lymphoid.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Dermatology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - liposomal doxorubicin is the correct answer, not sirolimus. The vignette describes classic AIDS-related Kaposi sarcoma (KS): HIV-positive patient with violaceous plaques, spindle cells on biopsy, and HHV-8 positivity. Key discriminating findings clearly establish KS diagnosis requiring systemic therapy. For systemic KS in HIV patients, liposomal doxorubicin (pegylated liposomal doxorubicin or liposomal daunorubicin) is the FDA-approved first-line chemotherapy with established efficacy and safety profile. Sirolimus (mTOR inhibitor) has shown activity in transplant-associated KS and some case reports in AIDS-KS, but it is NOT standard first-line therapy and lacks the evidence base of liposomal anthracyclines. The explanation incorrectly prioritizes sirolimus over proven chemotherapy. Interferon-alpha has historical use but inferior efficacy/tolerability. Thalidomide is investigational with significant toxicity. Rituximab treats B-cell lymphomas, not KS. Medical accuracy issue: The keyed answer contradicts standard oncology guidelines that establish liposomal doxorubicin as first-line systemic therapy for AIDS-KS. Minimal fix: Change the correct answer key from D (Sirolimus) to A (Liposomal doxorubicin) to align with current treatment standards.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - liposomal doxorubicin is the correct answer, not sirolimus. The vignette describes classic AIDS-related Kaposi sarcoma (KS): HIV-positive patient with violaceous plaques, spindle cells on biopsy, and HHV-8 positivity. Key discriminating findings clearly establish KS diagnosis requiring systemic therapy. For systemic KS in HIV patients, liposomal doxorubicin (pegylated liposomal doxorubicin or liposomal daunorubicin) is the FDA-approved first-line chemotherapy with established efficacy and safety profile. Sirolimus (mTOR inhibitor) has shown activity in transplant-associated KS and some case reports in AIDS-KS, but it is NOT standard first-line therapy and lacks the evidence base of liposomal anthracyclines. The explanation incorrectly prioritizes sirolimus over proven chemotherapy. Interferon-alpha has historical use but inferior efficacy/tolerability. Thalidomide is investigational with significant toxicity. Rituximab treats B-cell lymphomas, not KS. Medical accuracy issue: The keyed answer contradicts standard oncology guidelines that establish liposomal doxorubicin as first-line systemic therapy for AIDS-KS. Minimal fix: Change the correct answer key from D (Sirolimus) to A (Liposomal doxorubicin) to align with current treatment standards.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T182308874Z_grok-4-0709_seed129", "question_id": "20251216T182308874Z_grok-4-0709_seed129-020", "question": "A 60-year-old man with chronic kidney disease stage 4 presents with hematuria and flank pain. Imaging shows a Bosniak IV cyst with enhancing nodule. What is the most appropriate management?", "options": ["Partial nephrectomy", "Active surveillance", "Radiofrequency ablation", "Percutaneous biopsy", "Radical nephrectomy"], "answer": "A", "answer_index": 0, "explanation": "Partial nephrectomy preserves renal function in CKD while addressing malignant potential of Bosniak IV cyst. Surveillance for lower categories, ablation for small tumors, biopsy diagnostic not therapeutic, radical sacrifices nephrons.", "generator_model": "grok-4-0709", "seed": 129, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Urology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 60-year-old man with CKD stage 4 (eGFR 15-29 mL/min) and a Bosniak IV cyst with enhancing nodule, which carries ~90% malignancy risk and warrants surgical intervention. Key discriminating findings: advanced CKD (stage 4), malignant-potential renal lesion (Bosniak IV). The keyed answer (A: partial nephrectomy) aims to preserve nephron mass in advanced CKD while treating malignancy. However, option E (radical nephrectomy) is equally defensible. In CKD stage 4, the decision between partial versus radical nephrectomy depends on critical unstated factors: tumor size, location (polar vs. central), complexity score, contralateral kidney function, and technical feasibility. For complex/large/central Bosniak IV lesions in CKD stage 4, radical nephrectomy may be preferred to ensure oncologic control, accepting dialysis risk. For small peripheral lesions, partial nephrectomy is preferred. Without tumor characteristics, both surgical options are defensible. Medical accuracy: The rationale correctly identifies Bosniak IV malignancy risk and nephron-sparing principles but oversimplifies the nuanced surgical decision in advanced CKD. Minimal fix: Specify tumor size (e.g., '3 cm peripheral lower-pole lesion') to uniquely favor partial nephrectomy.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 60-year-old man with CKD stage 4 (eGFR 15-29 mL/min) and a Bosniak IV cyst with enhancing nodule, which carries ~90% malignancy risk and warrants surgical intervention. Key discriminating findings: advanced CKD (stage 4), malignant-potential renal lesion (Bosniak IV). The keyed answer (A: partial nephrectomy) aims to preserve nephron mass in advanced CKD while treating malignancy. However, option E (radical nephrectomy) is equally defensible. In CKD stage 4, the decision between partial versus radical nephrectomy depends on critical unstated factors: tumor size, location (polar vs. central), complexity score, contralateral kidney function, and technical feasibility. For complex/large/central Bosniak IV lesions in CKD stage 4, radical nephrectomy may be preferred to ensure oncologic control, accepting dialysis risk. For small peripheral lesions, partial nephrectomy is preferred. Without tumor characteristics, both surgical options are defensible. Medical accuracy: The rationale correctly identifies Bosniak IV malignancy risk and nephron-sparing principles but oversimplifies the nuanced surgical decision in advanced CKD. Minimal fix: Specify tumor size (e.g., '3 cm peripheral lower-pole lesion') to uniquely favor partial nephrectomy.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}]